Home » Stocks » ENTX

Entera Bio Ltd. (ENTX)

Stock Price: $1.05 USD -0.03 (-2.78%)
Updated Oct 28, 2020 1:00 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 19.15M
Revenue (ttm) 236,000
Net Income (ttm) -10.80M
Shares Out 18.23M
EPS (ttm) -0.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 28, 2020
Last Price $1.05
Previous Close $1.08
Change ($) -0.03
Change (%) -2.78%
Day's Open 1.08
Day's Range 1.05 - 1.09
Day's Volume 18,566
52-Week Range 1.00 - 3.40

More Stats

Market Cap 19.15M
Enterprise Value 4.26M
Earnings Date (est) Apr 1, 2021
Ex-Dividend Date n/a
Shares Outstanding 18.23M
Float 10.63M
EPS (basic) 0.89
EPS (diluted) -0.82
FCF / Share -0.74
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 70,292
Short Ratio 0.41
Short % of Float 0.66%
Beta 1.32
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 81.13
PB Ratio 2.72
Revenue 236,000
Operating Income -11.45M
Net Income -10.80M
Free Cash Flow -8.96M
Net Cash 14.89M
Net Cash / Share 0.82
Gross Margin 10.16%
Operating Margin -4,853.39%
Profit Margin -4,574.20%
FCF Margin -3,796.19%
ROA -77.73%
ROE -183.14%
ROIC 1,592.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

Current: $1.05
Target: 4.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-52.8%---
Gross Profit0.030.50--
Operating Income-11.45-10.86-11.34-5.37
Net Income-10.80-10.30-11.20-1.20
Shares Outstanding12.157.964.494.47
Earnings Per Share0.891.312.490.78
EPS Growth-32.06%-47.39%219.23%-
Operating Cash Flow-8.92-9.80-4.53-3.14
Capital Expenditures-0.04-0.07-0.05-0.04
Free Cash Flow-8.96-9.86-4.58-3.18
Cash & Equivalents15.1911.5211.754.16
Total Debt0.30-3.8914.72
Net Cash / Debt14.8911.527.85-10.56
Book Value11.9210.12-31.56-25.25
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Entera Bio Ltd.
Country Israel
Employees 19
CEO Roger J. Garceau

Stock Information

Ticker Symbol ENTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ENTX
IPO Date June 28, 2018


Entera Bio, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.